Apellis Pharmaceuticals Inc (APLS.OQ)
APLS.OQ on NASDAQ Stock Exchange Global Select Market
21.17USD
14 Jun 2019
21.17USD
14 Jun 2019
Change (% chg)
$-0.22 (-1.03%)
$-0.22 (-1.03%)
Prev Close
$21.39
$21.39
Open
$21.29
$21.29
Day's High
$21.50
$21.50
Day's Low
$21.07
$21.07
Volume
66,301
66,301
Avg. Vol
98,458
98,458
52-wk High
$24.78
$24.78
52-wk Low
$11.45
$11.45
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2019 | Mar '19 | 0.00 | -0.874 |
| FY 2018 | Dec '18 | 0.00 | -0.648 |
| Sep '18 | 0.00 | -0.640 | |
| Jun '18 | 0.00 | -0.609 | |
| Mar '18 | 0.00 | -0.432 | |
| FY 2017 | Dec '17 | 0.00 | -0.371 |
| Sep '17 | 0.00 | -0.235 | |
| Jun '17 | 0.00 | -0.246 | |
| Mar '17 | 0.00 | -0.184 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-19 | 3 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Sep-19 | 3 | 0.00 | 0.00 | 0.00 | 0.00 |
| Year Ending Dec-19 | 4 | 0.00 | 0.00 | 0.00 | 0.00 |
| Year Ending Dec-20 | 3 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earnings (per share) | |||||
| Quarter Ending Jun-19 | 4 | -0.77 | -0.68 | -0.83 | -0.57 |
| Quarter Ending Sep-19 | 4 | -0.78 | -0.69 | -0.88 | -0.61 |
| Year Ending Dec-19 | 5 | -3.15 | -2.90 | -3.51 | -1.93 |
| Year Ending Dec-20 | 4 | -3.35 | -2.80 | -3.91 | -2.10 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 32.88 | 37.45 | |
| P/E High - Last 5 Yrs. | -- | 50.25 | 57.55 | |
| P/E Low - Last 5 Yrs. | -- | 27.54 | 28.57 | |
| Beta | -- | 0.97 | 0.96 | |
| Price to Sales (TTM) | -- | 8.18 | 10.02 | |
| Price to Book (MRQ) | 5.95 | 3.94 | 4.53 | |
| Price to Tangible Book (MRQ) | 5.96 | 4.23 | 5.33 | |
| Price to Cash Flow (TTM) | -- | 23.85 | 26.07 | |
| % Owned Institutions | -- | 0.00 | 0.00 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.78 | 1.61 | |
| Dividend Yield - 5 Year Avg | -- | 1.47 | 1.35 | |
| Dividend 5 Year Growth Rate | -- | 6.38 | 6.52 | |
| Payout Ratio(TTM) | -- | 41.21 | 36.85 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -- | 13.51 | 15.38 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -- | 6.63 | 8.69 | |
| Sales - 5 Yr. Growth Rate | -- | 9.13 | 10.31 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -102.36 | 17.53 | 18.28 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -115.90 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 5.50 | 7.10 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 6.89 | 7.93 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 2.47 | 2.47 |
| Current Ratio (MRQ) | 15.23 | 3.47 | 3.43 |
| LT Debt to Equity (MRQ) | 2.97 | 13.07 | 14.00 |
| Total Debt to Equity (MRQ) | 2.97 | 18.23 | 19.69 |
| Interest Coverage (TTM) | -119.74 | 7.42 | 15.40 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 51.34 | 50.06 | |
| Gross Margin - 5 Yr. Avg. | -- | 50.39 | 51.22 | |
| EBITD Margin (TTM) | -- | -- | -- | |
| EBITD - 5 Yr. Avg | -- | 17.42 | 16.15 | |
| Operating Margin (TTM) | -- | -2.54 | -7.35 | |
| Operating Margin - 5 Yr. Avg. | -- | 13.70 | 11.44 | |
| Pre-Tax Margin (TTM) | -- | -3.03 | -7.82 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | 19.61 | 16.14 | |
| Net Profit Margin (TTM) | -- | -6.71 | -11.61 | |
| Net Profit Margin - 5 Yr. Avg. | -- | 14.74 | 11.33 | |
| Effective Tax Rate (TTM) | -- | 19.77 | 20.12 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 22.71 | 24.36 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 0 | 929,563,308 | 786,836,669 | |
| Net Income/Employee (TTM) | -1,797,015 | 108,751,581 | 92,111,001 | |
| Receivable Turnover (TTM) | -- | 5.56 | 5.85 | |
| Inventory Turnover (TTM) | -- | 2.57 | 3.71 | |
| Asset Turnover (TTM) | 0.00 | 0.85 | 0.82 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -64.93 | 10.07 | 9.71 | |
| Return on Assets - 5 Yr. Avg. | -71.76 | 11.23 | 10.70 | |
| Return on Investment (TTM) | -68.89 | 12.53 | 12.16 | |
| Return on Investment - 5 Yr. Avg. | -76.64 | 14.28 | 13.61 | |
| Return on Equity (TTM) | -88.38 | 13.82 | 16.93 | |
| Return on Equity - 5 Yr. Avg. | -291.97 | 15.53 | 15.13 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -- | -- | -- |
| EPS (TTM) % | -126.36 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Apellis Pharmaceuticals Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 17.61 | 16.49 | 99 | 88 |
| 13 Week | 12.43 | 9.92 | 99 | 20 |
| 26 Week | 13.27 | 2.01 | 99 | 26 |
| 52 Week | -4.08 | -7.55 | 99 | 71 |
| YTD | 60.50 | 39.37 | 99 | 26 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
Institutional Holders
| % Shares Owned: | 65.63% |
| # of Holders: | 141 |
| Total Shares Held: | 41,498,591 |
| 3 Mo. Net Change: | 8,077,471 |
| # New Positions: | 20 |
| # Closed Positions: | 21 |
| # Increased Positions: | 71 |
| # Reduced Positions: | 57 |
| # Net Buyers: | 14 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.